JP7839790B2 - Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体 - Google Patents

Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体

Info

Publication number
JP7839790B2
JP7839790B2 JP2023528245A JP2023528245A JP7839790B2 JP 7839790 B2 JP7839790 B2 JP 7839790B2 JP 2023528245 A JP2023528245 A JP 2023528245A JP 2023528245 A JP2023528245 A JP 2023528245A JP 7839790 B2 JP7839790 B2 JP 7839790B2
Authority
JP
Japan
Prior art keywords
represented
pyrazine
pyrazolo
nitrogen
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023528245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549360A (ja
JP2023549360A5 (https=
Inventor
ホプキンス，ブライアン・ティー
マー，ビン
マークス，アイザック
シュルツ，ユルゲン
ベンデバー，ジョージ
プリンス，ロビン
ネバライネン，マルタ
チェン，テユ
ユーサフ，ザイン
ヒンメルバウアー，マーティン
パッタロポン，バティー
ジョーンズ，ジョン・ハワード
リン，エドワード・イン－シアン
ゴンザレス・ロペス・デ・ツーリオ，フェリクス
パーゲット，トーマス
カパッチ，アンドリュー・ジョージ
シアボラ，シモーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2023549360A publication Critical patent/JP2023549360A/ja
Publication of JP2023549360A5 publication Critical patent/JP2023549360A5/ja
Application granted granted Critical
Publication of JP7839790B2 publication Critical patent/JP7839790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023528245A 2020-11-13 2021-11-12 Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体 Active JP7839790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13
US63/113,515 2020-11-13
PCT/US2021/059168 WO2022104079A1 (en) 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors

Publications (3)

Publication Number Publication Date
JP2023549360A JP2023549360A (ja) 2023-11-24
JP2023549360A5 JP2023549360A5 (https=) 2024-11-15
JP7839790B2 true JP7839790B2 (ja) 2026-04-02

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528245A Active JP7839790B2 (ja) 2020-11-13 2021-11-12 Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体

Country Status (14)

Country Link
US (1) US20240083900A1 (https=)
EP (1) EP4244223A1 (https=)
JP (1) JP7839790B2 (https=)
KR (1) KR20230119134A (https=)
CN (1) CN116783199A (https=)
AR (1) AR124048A1 (https=)
AU (1) AU2021377891A1 (https=)
BR (1) BR112023009116A2 (https=)
CL (1) CL2023001367A1 (https=)
CO (1) CO2023007677A2 (https=)
MX (1) MX2023005626A (https=)
TW (1) TW202233624A (https=)
UY (1) UY39517A (https=)
WO (1) WO2022104079A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086575A1 (en) * 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
CN116693357B (zh) * 2023-06-07 2026-01-27 西安工程大学 一种β-三氟甲基不饱和酰胺及其合成方法
WO2025049254A1 (en) * 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
CN118955332A (zh) * 2024-07-31 2024-11-15 德阳悦合生物医药科技有限公司 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535067A (ja) 2000-04-28 2003-11-25 バイエル アクチェンゲゼルシャフト イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
JP2014528475A (ja) 2011-10-12 2014-10-27 アレイ バイオファーマ、インコーポレイテッド ５，７置換イミダゾ［１，２−ｃ］ピリミジン
JP2016531119A (ja) 2013-07-31 2016-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
JP2017511365A (ja) 2014-04-17 2017-04-20 アッヴィ・インコーポレイテッド 複素環キナーゼ阻害薬
WO2020114487A1 (en) 2018-12-07 2020-06-11 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266908C (en) * 1996-09-27 2010-07-20 Joseph E. Saavedra O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535067A (ja) 2000-04-28 2003-11-25 バイエル アクチェンゲゼルシャフト イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
JP2014528475A (ja) 2011-10-12 2014-10-27 アレイ バイオファーマ、インコーポレイテッド ５，７置換イミダゾ［１，２−ｃ］ピリミジン
JP2016531119A (ja) 2013-07-31 2016-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
JP2017511365A (ja) 2014-04-17 2017-04-20 アッヴィ・インコーポレイテッド 複素環キナーゼ阻害薬
WO2020114487A1 (en) 2018-12-07 2020-06-11 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Also Published As

Publication number Publication date
CL2023001367A1 (es) 2024-01-05
JP2023549360A (ja) 2023-11-24
CO2023007677A2 (es) 2023-09-08
TW202233624A (zh) 2022-09-01
BR112023009116A2 (pt) 2023-10-03
CN116783199A (zh) 2023-09-19
AR124048A1 (es) 2023-02-08
MX2023005626A (es) 2023-07-31
KR20230119134A (ko) 2023-08-16
UY39517A (es) 2022-06-30
WO2022104079A1 (en) 2022-05-19
US20240083900A1 (en) 2024-03-14
AU2021377891A1 (en) 2023-07-06
EP4244223A1 (en) 2023-09-20
AU2021377891A9 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP7839790B2 (ja) Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体
US12077536B2 (en) BCL-2 inhibitors
US12168058B2 (en) Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
JP2024519496A (ja) ブルトンのチロシンキナーゼの分解を標的化するための化合物
MD4649C1 (ro) Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
US20240150349A1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
TW202315870A (zh) 布魯頓氏酪胺酸激酶之抑制劑
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
US20240374606A1 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
JP7779900B2 (ja) Ｂｔｋ阻害剤
WO2025081045A9 (en) Cysteine covalent modifiers of akt1 and uses thereof
RU2858502C2 (ru) Производные пиразол[1,5-a]пиразина в качестве ингибиторов втк
US20250270209A1 (en) Lrrk2 inhibitors
JP2024544530A (ja) Ｂｔｋ阻害剤
TW202600555A (zh) 作為itk抑制劑的雜雙環衍生物
EA047837B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260323

R150 Certificate of patent or registration of utility model

Ref document number: 7839790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150